Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.

BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long...

Full description

Bibliographic Details
Main Authors: Mariano Provencio, Pilar Sabín, Jose Gomez-Codina, Maria Torrente, Virginia Calvo, Marta Llanos, Josep Gumá, Cristina Quero, Ana Blasco, Miguel Angel Cruz, David Aguiar, Francisco García-Arroyo, Javier Lavernia, Natividad Martinez, Manuel Morales, Alvaro Saez-Cusi, Delvys Rodriguez, Luis de la Cruz, Jose Javier Sanchez, Antonio Rueda, GOTEL (Spanish Lymphoma Oncology Group)
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5426713?pdf=render
id doaj-6e236207a74245ef906d5faa5f1d0dde
record_format Article
spelling doaj-6e236207a74245ef906d5faa5f1d0dde2020-11-25T01:59:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017720410.1371/journal.pone.0177204Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.Mariano ProvencioPilar SabínJose Gomez-CodinaMaria TorrenteVirginia CalvoMarta LlanosJosep GumáCristina QueroAna BlascoMiguel Angel CruzDavid AguiarFrancisco García-ArroyoJavier LaverniaNatividad MartinezManuel MoralesAlvaro Saez-CusiDelvys RodriguezLuis de la CruzJose Javier SanchezAntonio RuedaGOTEL (Spanish Lymphoma Oncology Group)BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. PATIENTS AND METHODS:A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. RESULTS:Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p <0.03), age < 60 years (p <0.0001), low FLIPI (p <0.002), normal β2 microglobulin (p <0.005), no B symptoms upon diagnosis (p <0.02), Performance Status 0-1 (p <0.03) and treatment with anthracyclines and rituximab (p <0.001), or rituximab (p <0.0001). CONCLUSIONS:A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.http://europepmc.org/articles/PMC5426713?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Mariano Provencio
Pilar Sabín
Jose Gomez-Codina
Maria Torrente
Virginia Calvo
Marta Llanos
Josep Gumá
Cristina Quero
Ana Blasco
Miguel Angel Cruz
David Aguiar
Francisco García-Arroyo
Javier Lavernia
Natividad Martinez
Manuel Morales
Alvaro Saez-Cusi
Delvys Rodriguez
Luis de la Cruz
Jose Javier Sanchez
Antonio Rueda
GOTEL (Spanish Lymphoma Oncology Group)
spellingShingle Mariano Provencio
Pilar Sabín
Jose Gomez-Codina
Maria Torrente
Virginia Calvo
Marta Llanos
Josep Gumá
Cristina Quero
Ana Blasco
Miguel Angel Cruz
David Aguiar
Francisco García-Arroyo
Javier Lavernia
Natividad Martinez
Manuel Morales
Alvaro Saez-Cusi
Delvys Rodriguez
Luis de la Cruz
Jose Javier Sanchez
Antonio Rueda
GOTEL (Spanish Lymphoma Oncology Group)
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
PLoS ONE
author_facet Mariano Provencio
Pilar Sabín
Jose Gomez-Codina
Maria Torrente
Virginia Calvo
Marta Llanos
Josep Gumá
Cristina Quero
Ana Blasco
Miguel Angel Cruz
David Aguiar
Francisco García-Arroyo
Javier Lavernia
Natividad Martinez
Manuel Morales
Alvaro Saez-Cusi
Delvys Rodriguez
Luis de la Cruz
Jose Javier Sanchez
Antonio Rueda
GOTEL (Spanish Lymphoma Oncology Group)
author_sort Mariano Provencio
title Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
title_short Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
title_full Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
title_fullStr Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
title_full_unstemmed Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
title_sort impact of treatment in long-term survival patients with follicular lymphoma: a spanish lymphoma oncology group registry.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description BACKGROUND:Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. PATIENTS AND METHODS:A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. RESULTS:Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p <0.03), age < 60 years (p <0.0001), low FLIPI (p <0.002), normal β2 microglobulin (p <0.005), no B symptoms upon diagnosis (p <0.02), Performance Status 0-1 (p <0.03) and treatment with anthracyclines and rituximab (p <0.001), or rituximab (p <0.0001). CONCLUSIONS:A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.
url http://europepmc.org/articles/PMC5426713?pdf=render
work_keys_str_mv AT marianoprovencio impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT pilarsabin impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT josegomezcodina impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT mariatorrente impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT virginiacalvo impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT martallanos impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT josepguma impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT cristinaquero impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT anablasco impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT miguelangelcruz impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT davidaguiar impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT franciscogarciaarroyo impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT javierlavernia impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT natividadmartinez impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT manuelmorales impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT alvarosaezcusi impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT delvysrodriguez impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT luisdelacruz impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT josejaviersanchez impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT antoniorueda impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
AT gotelspanishlymphomaoncologygroup impactoftreatmentinlongtermsurvivalpatientswithfollicularlymphomaaspanishlymphomaoncologygroupregistry
_version_ 1724963942994804736